The Ongoing Impact of MFN Pricing

Alice Valder Curran joined the Pharmaceutical Executive Podcast to discuss the ongoing strategizing for MFN pricing in the pharma industry. With the launch of TrumpRx, the industry has a better idea of what the administration is looking for in negotiations. However, recent tariff rulings could impact the primary way the administration has enforced its position in negotiations.

• MFN pricing is still evolving as comments are due on the proposed rules for the globe and guard model.
• Manufacturers have long had processes for providing price reductions to patients, including paper coupons and co-pay assistance cards.
• MFN may prevent some companies from launching drugs in global markets if they can’t make the pricing work with MFN pricing in the US.
• The Supreme Court’s decision on tariffs was on IEEPA tariffs, while the administration's MFN negotiations involve section 232 tariffs.